BLOCKADE BY ORAL OR PARENTERAL RPR-100893 (A NONPEPTIDE NK1 RECEPTOR ANTAGONIST) OF NEUROGENIC PLASMA-PROTEIN EXTRAVASATION WITHIN GUINEA-PIG DURA-MATER AND CONJUNCTIVA

1 The ability of an NK1 receptor antagonist, RPR 100893, and its enantiomer, RPR 103253 to block neurogenic plasma protein extravasation in guinea-pig dura mater and conjunctiva was assessed following I-125-labelled bovine serum albumin ([I-125]-BSA, 50 mu Ci kg(-1), i.v.) and unilateral electrical stimulation of the trigeminal ganglion (0.6 mA, 5 ms, 5 Hz, 5 min) or capsaicin administration (150 mu g kg(-1), i.v.). 2 When administered p.o. 60 min prior to electrical stimulation, RPR 100893 (greater than or equal to 0.1 mu g kg(-1)) decreased plasma protein extravasation in dura mater in a dose-dependent manner, whereas the enantiomer (10 or 100 mu g kg(-1), p.o.) was inactive. 3 When given i.v. 30 min prior to electrical stimulation, RPR 100893 (greater than or equal to 0.5 ng kg(-1)) significantly inhibited plasma protein extravasation in the dura mater evoked by electrical stimulation in a dose-dependent manner. 4 RPR 100893 (100 mu g kg(-1), p.o.) also reduced the leakage when given 45 min before the guinea-pigs were killed and 10, 40 and 80 min after electrical trigeminal stimulation. 5 RPR 100893 given p.o. dose-dependently inhibited capsaicin-induced plasma protein extravasation with ID(50)s of 7.4 mu g kg(-1) and 82 mu g kg(-1) for dura mater and conjunctiva, respectively. 6 These results are consistent with the contention that NK1 receptors mediate neurogenic plasma protein leakage following trigeminal stimulation, and suggest that NK1 receptor antagonists of the perhydroisoindolone series may be useful for treating migraine and cluster headaches.